Incretin therapy for type 2 diabetes in Spain: A cost-effectiveness analysis of liraglutide versus sitagliptin

Diabetes Therapy

Volumn 4, Issue 2, 2013, Pages 417-430

  Raya, Pedro Mezquita ^a   Pérez, Antonio ^b   De Arellano, Antonio Ramírez ^c   Briones, Teresa ^c   Hunt, Barnaby ^d   Valentine, William J ^d  

^a HOSPITAL TORRECÁRDENAS   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c NOVO NORDISK A S   (Denmark)

^d Ossian Health Economics and Communications   (Switzerland)

Author keywords

Cost; Cost effectiveness; DPP 4; GLP 1; Incretin; Liraglutide; Sitagliptin; Spain; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INCRETIN; LIRAGLUTIDE; SITAGLIPTIN;

ADULT; ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; DRUG COST; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; LIFE EXPECTANCY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SPAIN; SYSTOLIC BLOOD PRESSURE;

EID: 84899819729     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0044-9     Document Type: Article

References (34)

1. Soriguer F, Goday A, Bosch-Comas A, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bete.es study. Diabetologia. 2012;55:88-93.
2. International Diabetes Federation. IDF diabetes atlas. 5th ed. Brussels: International Diabetes Federation; 2011.
3. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:293-301.
4. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93.
5. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91.
6. Gaede P, Valentine WJ, Palmer AJ, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care. 2008;31:1510-5.
7. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-72.
8. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-705.
9. Pratley RE, Nauck M, Bailey T, the 1860-LIRA-DPP-4 Study Group, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447-56.
10. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decisionmaking. Curr Med Res Opin. 2004;20(Suppl 1):5-26.
11. Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20(Suppl 1):27-40.
12. Foos V, Palmer JL, Grant D, Lloyd A, Lamotte M, McEwan P. PRM58 long-term validation of the IMS CORE Diabetes Model in type 1 and type 2 diabetes. Value Health. 2012;15:A470.
13. Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics. 2003;21:651-9.
14. Arós F, Loma-Osorio A, Alonso A, et al. Guías de actuación clínica de la Sociedad Española de Cardiología en el infarto agudo de miocardio. Rev Esp Cardiol. 1999;52:919-56.
15. Lopez-Bastida J, Aguilar S, Alvarez M, Gonzalez D. The economic burden of stroke in Spain. Value Health. 2003;6:615.
16. Arrieta J. Evaluación económica del tratamiento sustitutivo renal (hemodiálisis, diálisis peritoneal y trasplante) en España. Nefrologia. 2010;1(Supl Ext 1):37-47.
17. Hammer M, Lammert M, Mejías SM, Kern W, Frier BM. Costs of severe hypoglycaemia in three European countries. J Med Econ. 2009;12:281-90.
18. Curtis JR, To T, Muirhead S, Cummings E, Daneman D. Recent trends in hospitalization for diabetic ketoacidosis in Ontario children. Diabetes Care. 2002;25:1591-6.
19. Oliva J, Lobo F, Molina B, Monereo S. Estudio de los costes directos sanitarios de los pacientes con diabetes mellitus en España. Diabetes Care. 2004;27:2616-21.
20. Castells X, Alonso J, Castilla M, Ribó C, Cots F, Antó JM. Outcomes and costs of outpatient and inpatient cataract surgery: a randomised clinical trial. J Clin Epidemiol. 2001;54:23-9.
21. Ministerio de Sanidad, Politica Social e Igualdad, Grupos Relacionados de Diagnóastico (GRD), 2008 http://www.msps.es/estadEstudios/estadisticas/docs/PESOS_ESPANOLES_AP_GRD_V23_2008.pdf.
22. Davies MJ, Chubb BD, Valentine WJ. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabet Med. 2012;29:313-20.
23. López-Bastida J, Oliva J, Anto Ëoeanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010;11:513-20.
24. Pratley RE, Nauck MA, Bailey T, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35:1986-93.
25. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
26. Lee WC, Samyshkin Y, Langer J, Palmer JL. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. J Med Econ. 2012;15(Suppl 2):28-37.
27. Jin HY, Liu WJ, Park JH, Baek HS, Park TS. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res. 2009;40:536-44.
28. Mezquita-Raya P, López de la Torre Casares M, Moreno Pérez O. D.M. Diabetes WorkGroup. Liraglutide in patients with DM2 and obesity previously treated with oral antidiabetic agents: eDM Spain SEEN Study. Abstract accepted at International Diabetes Federation World Diabetes Congress. December 2-6, 2013, Melbourne, Australia. Abstract number: ME-0182.
29. Bergenstal RM, Forti A, Chiasson J et al. Once weekly taspoglutide, a human GLP-1 analog, is superior to sitagliptin in improving glycaemic control and weight loss in patients with type 2 diabetes (T2D): results from the T-emerge 4 trial. Diabetes 2010;59(Suppl. 1):A16 (58-OR).
30. Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376:431-9.
31. Malmenäs M, Bouchard JR, Langer J. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 lg. Clin Ther. 2013;35:795-807.
32. Pelletier EM, Pawaskar M, Smith PJ, Best JH, Chapman RH. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis. J Med Econ. 2012;15:1039-50.
33. Gafni A, Birch S, Mehrez A. Economics, health and health economics: HYEs (healthy-years equivalent) versus QALYs (quality-adjusted live-year). J Health Econ. 1993;12:325-39.
34. Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013;36:2254-61.